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Abstract: Type I collagen, the predominant protein of vertebrates, assembles into fibrils that or-
chestrate the form and function of bone, tendon, skin, and other tissues. Collagen plays roles in
hemostasis, wound healing, angiogenesis, and biomineralization, and its dysfunction contributes to
fibrosis, atherosclerosis, cancer metastasis, and brittle bone disease. To elucidate the type I collagen
structure-function relationship, we constructed a type I collagen fibril interactome, including its
functional sites and disease-associated mutations. When projected onto an X-ray diffraction model of
the native collagen microfibril, data revealed a matrix interaction domain that assumes structural
roles including collagen assembly, crosslinking, proteoglycan (PG) binding, and mineralization, and
the cell interaction domain supporting dynamic aspects of collagen biology such as hemostasis,
tissue remodeling, and cell adhesion. Our type III collagen interactome corroborates this model. We
propose that in quiescent tissues, the fibril projects a structural face; however, tissue injury releases
blood into the collagenous stroma, triggering exposure of the fibrils’ cell and ligand binding sites
crucial for tissue remodeling and regeneration. Applications of our research include discovery of
anti-fibrotic antibodies and elucidating their interactions with collagen, and using insights from our
angiogenesis studies and collagen structure-function model to inform the design of super-angiogenic
collagens and collagen mimetics.
Keywords: type I collagen; type III collagen; interactome; microfibril; ligand binding; extracellular
matrix; connective tissue; fibrosis; angiogenesis; hemostasis; therapeutic antibodies
1. Introduction
Collagens are among the most ubiquitous and complex of the vertebrate extracellu-
lar matrix (ECM) macromolecules [1–5]. About thirty genetically distinct collagens are
expressed in human connective tissues. For most, the majority of their sequences exist as
triple helices, which makes them unique among proteins. Triple helices are rigid, rope-like
protein conformations which, depending on the collagen type, may be interspersed be-
tween small flexible non-triple helical regions, or larger, globular non-collagenous regions.
The triple helical regions are composed of contiguous Gly-X-Y tripeptide repeats, with Gly
residues being supported at this position because they are small enough to fit the confines
of the three peptide chains that form the triple helix. The extent of the triple helical region,
along with the presence of non-triple helical regions, determines the type of aggregate
collagen molecules make, and how they contribute to the intricate ECM scaffold that makes
up the internal architecture of the vertebrate body.
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Type I collagen is the prototypical collagen that aggregates into fibrils. It is the
most abundant protein in the human body, comprising about 7 kg of the dry weight of
the human adult. There are approximately 1 × 1023 collagen molecules in the human
body [6]. Remarkably, if the collagen molecules from an adult human were laid end to
end, the resulting rope would be long enough to lasso the Moon from the Earth many
times over, or easily span the distance between the Earth and the Sun [7]. That so many
collagen molecules are packed tightly within one organism is a testament to the exquisite
and efficient way vertebrate cells assemble and twist collagen molecules into rope-like
fibrils—the most abundant molecular aggregate formed by collagens in vivo.
Type I collagen comprises much of the substance of connective tissues including
tendon, ligaments and skin, and most of the organic phase of bone, and supports and
provides form to many other tissues of the vertebrate body via the connective tissue
proper [1,3,8]. In bone, the type I collagen fibril also serves as the site for mineralization
either directly, or by its association with mineralization nucleation proteins [9–12]. It is
therefore no surprise that type I collagen plays crucial roles in vital physiologic processes,
including hemostasis, angiogenesis, and biomineralization, and in human pathologies
including cancer, fibrosis, and atherosclerosis [3,13,14]. Type I collagen from animal sources
is also the most widely used biomaterial for fabrication of bone regeneration scaffolds,
hemostats, bandages, and tendon repair patches [15]. Therefore, from both the basic
and applied standpoints, it is of paramount interest to understand collagen biology and
define the collagen structure-function relationship. Here we will review our research on
creating and analyzing type I collagen and type III collagen interactomes, and our use
of computational approaches to model these collagens’ molecular interactions with cells,
bioactive factors, and other macromolecules. Further, we will discuss how our findings
inform applications including the design and discovery of anti-fibrotic and pro-angiogenic
therapies.
2. Type I Collagen Structure and Assembly
Type I collagen is synthesized by cells as pro-α1 and pro-α2 procollagen chains,
encoded by separate genes and comprising about 1000 amino acid residues each [2].
The C-terminal propeptides promote the polymerization of two pro-α1 and one pro-α2
chains into the triple helical procollagen molecule. Extracellularly, the globular termini of
procollagen are removed by proteolysis, yielding trimeric collagen monomers of a little
over 300-nm long. Five monomers assemble in a quarter-staggered fashion to form the
microfibril, the basic subunit of the collagen fibril (Figure 1). Specifically, along the fibril’s
long axis exists a repeating D-period pattern of molecular organization. Within the 67-nm
D-period, groups of five neighboring collagen molecules wind around each other into
microfibrils that interdigitate with neighboring microfibrils to form practically inseparable
connections within the fibril. The amino acid sequences of the single collagen molecules
are found within each five-molecule segment that defines each D-period. Because ~300 nm
(collagen triple helix length)/67 nm (D-period length) produces a non-integer number,
the D-period contains a region of incomplete overlap, called the gap zone. This space
within the microfibril plays a role in the biomechanical properties of the fibril. The gap
region also allows biomineralization of bone by accommodating hydroxyapatite crystal
formation and growth [16,17]. Because of the gap zone, the remaining four full-length
segments arrange around each other forming a twist that somewhat mirrors the superhelix
of the collagen molecule, albeit on a larger scale [18]. Each microfibril (Figure 1B,C), and its
neighbors may be connected by N- and C-terminal intermolecular cross-links, yet, collagen
fibrils exhibit varying degrees of crosslinking depending on tissue location, age, and other
circumstances [3]. Other collagen types, proteoglycans (PGs), and matrix macromolecules
typically assemble onto the fibril to impart tissue-specific properties to the polymer [3,19].
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Figure 1. Type I collagen assembly and structure. (A). Segment of Type I collagen fibril visualized 
by transmission electron microscopy. One molecular repeat or D-period (D) is indicated. The posi-
tive stain microscopy bands, a–e, are as indicated below the image; arrow indicates left border of 
overlap zone. This fibril preparation was used to localize heparin-binding sites; thus, heparin-gold 
particles appear as dark circles bound to the fibril. Originally published in San Antonio et al., 1994, 
J. Cell Biol., 125, 1179–1188. (B). Fibril schematic depicted as negatively-stained TEM preparation 
where gap regions are dark and overlap regions light. Microfibril schematic shows the Hodge-
Petruska scheme [20] of packing where collagen molecules (numbered 1–5 for molecular (M) seg-
ments as in M1, M2, etc.) are staggered so that every five M segment does not traverse the entire 
D-period. Select collagen functional domains (right) are marked along the length of the collagen 
molecule. (C). A single D period of a single microfibril is shown beneath the microfibril schematic. 
The C-terminal telopeptide (marked in green on the top of the microfibril) and the rest of mono-
mer 5 is orientated towards the outside of the fibril. The side view is from an observers’ perspec-
tive from a neighboring microfibril. Note the molecular segments are relatively straight in the 
overlap zone but re-organize towards the end of the gap zone especially in the region of the super-
twist in the vicinity of the gap zone’s discoidin domain receptor 2 (DDR2) binding site. Figure 
segments reprinted with permission from [21]. 
Figure 1. Type I collagen assembly and structure. (A). Segment of Type I collagen fibril visualized by transmission electron
microscopy. One molecular repeat or D-period (D) is indicated. The positive stain microscopy bands, a–e, are as indicated
below the image; arrow indicates left border of overlap zone. This fibril preparation was used to localize heparin-binding
sites; thus, heparin-gold particles appear as dark circles bound to the fibril. Originally published in San Antonio et al., 1994,
J. Cell Biol., 125, 1179–1188. (B). Fibril schematic depicted as negatively-stained TEM preparation where gap regions are
dark and overlap re ions light. Microfibril schematic shows the Hodge-Pet uska scheme [20] of packing where collagen
molecules (numbered 1–5 for molecular (M) segments as in M1, M2, etc.) are staggered so that every five M segment does not
traverse the entire D-period. Select collag n functional domains (right) are mark d along the length of t collagen molecule.
(C). A single D period of a single microfibril is shown beneath the microfibril schematic. The C-terminal telopeptide (marked
in green on the top of the microfibril) and the rest of monomer 5 is orientated towards the outside of the fibril. The side
view is from an observers’ perspective from a neighboring microfibril. Note the molecular segments are relatively straight
in the overlap zone but re-organize towards the end of the gap zone especially in the region of the supertwist in the vicinity
of the gap zone’s discoidin domain receptor 2 (DDR2) binding site. Figure segments reprinted with permission from [21].
Bioengineering 2021, 8, 3 4 of 23
3. Creating a “Road Map” or Interactome of Type I Collagen
Over the past fifty years, a significant amount of information has been discovered
about type I collagen, including its primary sequences, post-translational modifications,
mechanisms of folding and polymerization, identification of its numerous binding partners,
and mutations that result in a spectrum of diseases [1,3,5]. Twenty years ago, one of our
labs began creating a type I collagen interactome in an effort to discover deep insights
into the collagen structure-function relationship [22]. For example, we hoped to clarify
the fundamental issues of whether type I collagen’s structural features, ligand binding
sites, and mutations are distributed randomly or non-randomly on the molecule, and
whether the protein has domains dedicated to specific functions. Furthermore, we wanted
to know if we could correlate the positions of mutations in the collagen molecule and the
disorders they cause, with their effect on protein expression or the disruption of a specific
protein function. As the basis for the interactome, we used a model representing collagen
monomer alignment within the fibril according to complementary electrostatic interactions,
resulting in a molecular overlap of approximately a quarter stagger between the monomers,
and zones of complete (overlap zone) and incomplete (gap zone) overlap [23] (Figure 1).
Thus, on the interactome, the primary sequences of the α1(I) and α2(I) chains of five
collagen molecules are arranged sequentially from the N-terminus to the C-terminus.
The collagen molecule was then annotated with known functional sites such as those
for intermolecular crosslinking, glycosylation, and matrix metalloproteinase-1 (MMP-1)
cleavage. Next, the proposed binding sites for dozens of collagen-binding ligands such
as cytokines, cell adhesion molecules, and proteoglycans were indicated. Finally, the
positions of substitution mutations associated with human diseases including osteogenesis
imperfecta (OI; brittle bone disease), Ehlers Danlos syndrome (EDS; although some EDS
mutations map to type I collagen’s N-terminal region, most map to type III collagen as
discussed later in this review), osteoporosis, and others were included (Figure 2). As
an outcome, our interactome incorporated hundreds of ligand binding sites, functional
domains, and human mutations [6,22].
A qualitative analysis of the collagen interactome revealed several observations. Par-
ticularly, ligand binding sites appear not to be randomly distributed as evidenced by at
least three hot spots for ligand binding where many ligands exhibit overlapping, or in
some cases, identical binding sites. On the other hand, some regions of the collagen fibril
exhibit few or no ligand binding sites. Because of their prominence, ligand binding hot
spots were named major ligand binding regions (MLBRs) [6]. Moreover, relatively more
ligand binding sites located to the C-terminal half of the collagen molecule.
Multivalency in the binding of several ligands to collagen seemed to be a theme (e.g.,
for the secreted protein rich in aspartic acid and cysteine, SPARC [24]; discoidin domain re-
ceptor 2, DDR2 [25,26]; and integrin binding sites [27,28] as such ligands displayed multiple
binding sites for collagen, each on different monomers of the fibril. Analysis of patterns of
ligand binding sites and mutation distributions revealed the collagen fibril to comprise two
distinct functional domains [22] (Figures 2 and 3). Most of the dynamic aspects of collagen
biology are proposed to occur in one region, called the “cell interaction domain”, which
occupies much of the fibril’s overlap zone. This domain includes sequences mediating the
binding of cell surface integrin receptors (a predominant mechanism of cell-collagen adhe-
sion and interactions), various bioactive factors, collagen scission/remodeling by MMP-1
(vertebrate collagenase), angiogenesis, and hemostasis (blood clotting). The remainder
of the fibril comprises the “matrix interaction domain”, proposed to assume a predom-
inantly structural role, where intermolecular crosslinking between collagen monomers
occurs, and PGs bind to regulate fibril solubility and inter-fibrillar spacing among other
functions [19,29]. Furthermore, the matrix interaction domain likely harbors the putative
sites where biomineralization initiates in tissues like bone. The mechanism of collagen
biomineralization remains elusive; substantial data support three non-mutually exclu-
sive hypotheses. The first maintains that the fibril contains several amino acid sequences
and post-translational modifications that may potentially nucleate hydroxyapatite min-
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eral [9–11,30–36]. Alternatively, several acidic non-collagenous bone phosphoproteins (e.g.,
SIBLING proteins such as osteopontin, bone sialoprotein, and phosphophoryn) are pro-
posed to associate with collagen to provide the mineralization substrate [12,37]. Finally, it
has been proposed that the spaces within and between the microfibrils may support biomin-
eralization without the need for mineralization nucleation sequences or collagen-associated
proteins [38–41].
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Figure 1. Cont.




Figure 2. (A) Type I collagen interactome. Human collagen primary sequences were from GenBank, accession #s: a1(I), 
NP000079; a2(I), NP000080 and aligned as described [23] (Figure 1). Ligand binding sites are indicated by rectangular 
boxes adjacent to relevant collagen sequences. Gray boxes denote ligand binding to the monomer. Non-shaded boxes 
Figure 2. (A) Type I collagen interactome. Human collagen pri ary sequences were from GenBank, accession #s: a1(I),
NP000079; a2(I), NP000080 and aligned as described [23] (Figure 1). Ligand binding sites are indicated by rectangular
boxes adjacent to relevant collagen sequences. Gray boxes denote ligand binding to the monomer. Non-shaded boxes
denote ligand binding to one α chain. Major ligand binding regions (MLBR) 1, 2, and 3 are designated. Disease-associated
mutations are indicated next to affected residues. Broad cross-fibril ligand binding regions are delineated by color-shaded
overlays. (B) Legend to type I collagen interactome (A) [22], listing abbreviations of mapped sites; literature citations are
in [22]. Human mutation data date to 2013. This figure was modified from research originally published in the J. Biol. Chem.
© the American Society for Biochemistry and Molecular Biology [22].
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COL1A1 and COL1A2 genes associated with OI, which is typically divided into four cate-
gories of disease severity: type I (mild), II (lethal), III (severe), and IV (moderately severe) 
[2]. This can be observed on the collagen interactome wherein the majority of mutations 
shown correspond to glycine (G) substitutions for another amino acid, as indicated above 
the triple helix for α1 chain mutations, or below for those on α2 (Figure 2). In addition, 
another category of OI mutations proposed to occur in type I collagen are “silent”, and 
assumed to have such severe consequences that affected individuals do not survive em-
bryonic development, and are therefore not seen in the clinic [42]. The consequences of 
collagen substitution mutations are mainly proposed to arise via one of several means. 
The “gradient” model suggests that during its intracellular assembly, since the collagen 
triple helix folds from the C terminus to the N terminus, mutations located more C-termi-
nal on the protein should affect collagen post-translational modifications and assembly 
more profoundly than those occurring in the N-terminal region, resulting in more severe 
phenotypes, which is typically observed [43]. Indeed, examination of the collagen interac-
tome illustrates that OI mutations at the N terminus tend to be milder, and as one moves 
toward the C terminus the frequency of lethal mutations increases. In contrast, the “re-
gional model” suggests that some mutations may directly disrupt specific functions of the 
mature protein resulting in disease pathologies [42,44]. Several possible examples of the 
Figure 3. Domain odel of c llagen fibril function. Type I collagen interactome (Figure 2) and X-ray
diffraction fibril model (Figure 4) suggests the conditional domain model of collagen fibril function.
Depending on the physiological state of the tissue, the fibril predominantly supports structural
duties including intermolecular crosslinking, proteoglycan binding, and biomineralization via the
matrix interaction domain; alternatively, dyna ic biological processes such as hemostasis, collagen
remodeling, and cell adhesio are supporte via the cell interaction domain, as sche atically shown
in Figure 5. This figure was originally published in the J. Biol. Chem. © the American Society for
Biochemistry and Molecular Biology [22].
Human Mutation Patterns
The most abundant mutations of type I collagen are glycine substitutions in the
COL1A1 and COL1A2 genes associated with OI, which is typically divided into four
categories of disease severity: type I (mild), II (lethal), III (severe), and IV (moderately
severe) [2]. This can be observed on the collagen interactome wherein the majority of
mutations shown correspond to glycine (G) substitutions for another amino acid, as in-
dicated above the triple helix for α1 chain mutations, or below for those on α2 (Figure 2).
In addition, another category of OI mutations proposed to occur in type I collagen are
“silent”, and assumed to have such severe consequences that affected individuals do not
survive embryo ic development, and are therefore not seen in the clinic [42]. The conse-
quences of collagen substitution mutations are mainly proposed to arise via one of several
means. The “gradient” model suggests that during its intracellular assembly, since the
collagen triple helix folds from the C terminus to the N terminus, mutations located more
C-terminal on the protein should affect collagen post-translational modifications and as-
sembly more profoundly than those occurring in the N-terminal region, resulting in more
severe phenotypes, which is typically observed [43]. Indeed, examination of the collagen
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interactome illustrates that OI mutations at the N terminus tend to be milder, and as one
moves toward the C terminus the frequency of lethal mutations increases. In contrast, the
“regional model” suggests that some mutations may directly disrupt specific functions of
the mature protein resulting in disease pathologies [42,44]. Several possible examples of
the latter were revealed by analysis of our collagen interactome. Thus, mutation silent
zones appear on collagen monomer 3 (Figure 2) flanking the preferred binding site for
αlβ1/α2β1 integrin receptors—GFOGER—and implying a critical functional role for this
sequence [22]. Moreover, on the α2(I) chain, clusters of lethal OI mutations alternate with
non-lethal ones, with the former corresponding to zones for the binding of PGs that play a
crucial role in fibril structure and biology [2]. Further, some consecutive runs of glycine
residues associated exclusively with lethal, non-lethal, or no mutations exist throughout
the protein, in no discernable pattern. Many of the non-OI, or “atypical” mutations also do
not exhibit a gradient of phenotype severity but rather, cluster to a few distinct zones on
the fibril [22].
4. Translating the Collagen Interactome into the Three-Dimensional (3D) “Living” Fibril
The two-dimensional (2D) type I collagen interactome cannot distinguish between
surface-exposed accessible sequences capable of interacting with cells and various bioactive
factors, and inaccessible ones located internally within the fibril. Therefore, we will examine
selected interactome data in the context of the X-ray diffraction model of the collagen
microfibril created by one of our research groups. Before doing so, we will introduce the
collagen microfibril structure in the context of the collagen fibril.
The collagen fibril is a crystalline construct, demonstrated by its ability to diffract
X-rays particularly when extracted from a tissue in a hydrated, minimally-strained
state [45–47]. The collagen microfibril model was determined from X-ray diffraction
analysis of rat tendon type I collagen molecules in situ [18]. Fiber diffraction data collected
from native and heavy atom-derivatized rat tail tendons were used to solve the structure
of the collagen molecules via multiple isomorphous replacement [22]. A molecular model
was constructed based on the primary sequences of the three α chains of type I collagen,
and superhelical parameters were determined from structural analyses of triple helical
peptide collagen models [18,48]. The electron density map representing the microfibril has
a resolution of 0.516 nm along the fiber axis and 1.11 nm perpendicular to that. Translating
the positions of functional sites from the collagen interactome to the three-dimensional
microfibril model was accomplished by performing solvent-accessible surface calculations
and rendering using SPOCK [49] with a 0.14 nm default probe size. The functional sites
were color-highlighted within this representation. The nearly identical sequence identity
between rat and human type I collagen justifies localizing functional sequences of human
type I collagen on the rat-based collagen structure.
Thus, to obtain a 3D, more physiologically relevant view of the collagen fibril we pro-
jected data from the interactome onto the collagen microfibril X-ray diffraction model [50]
(Figure 4). Significantly, it was discovered that the domain model indicated by analysis
of the interactome also held true for the native fibril. Next, we investigated surface-
accessible and inaccessible regions of the fibril and their associated binding sites. Thus,
surface accessibility of about a dozen functional sites was qualitatively ranked accord-
ing to a four-tiered scale ranging from high, moderate, low, to least accessible to water
molecules and small ions. For binding of ligands to the collagen fibrils, we identified some
unobstructed sites, including glycoprotein VI (GPVI) [51], Endo180 (sequence required
for endocytic recycling of collagen) [52,53], osteoclast-associated receptor (OSCAR; not
shown on collagen interactome) [54], P986 (3-prolyl hydroxylation at amino acid position
986 required for collagen folding and post-translational modifications) [55], fibrillogenesis
control sequences [56], residues mediating intermolecular crosslinking [3], and binding
sites for cartilage oligomeric matrix protein (COMP) [57] and pigment epithelium-derived
growth factor (PEDF) [58], which appear to co-locate at the interface of (GPO)5 at the
C-terminal end of the triple helix and the start of the non-helical C-telopeptide [21,59].
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Other unobstructed sequences of monomer 4 in the gap zone included the low affinity
integrin binding sequence, GASGER [27], and the small leucine rich proteoglycan (SLRP)
core protein binding sites [60] (Figure 4). Most of these sites are structural features involved
in collagen folding, assembly, regulation of fibril solubility and interfibrillar spacing, and
structural integrity. In contrast, (GPO)5 promotes hemostasis by ligating GPVI receptors
on platelet membranes [51].
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ecules [50]. Notably, the collagen sequences comprising the recessed portions or valleys 
of the fibril surface carry out structural duties, including sites for the binding of the 
decorin core protein [60], and in providing possible sites to nucleate and/or accommodate 
hydroxyapatite mineral growth in skeletal tissues. Thus, the exterior of the native collagen 
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stasis in response to tissue injury. 
Conditional Cell and Matrix Interaction Domains of the Type I Collagen Fibril 
Figure 4. Ranking of ligand accessibilities to crucial binding sites and functional sequences in the native and proteolyzed
type I collagen fibril. (A) Key functional domains of collagen were mapped onto a model of the fibril surface viewed from
the fibril’s exterior. A molecular accessibility ranking of various ligands to their binding sites was determined for the static
fibril, and following MMP-1 cleavage of M4 and “opening up” of the fibril. (B) View of the fibril’s GFOGER and Von
Willebrand’s Factor (vWF)-binding sites following MMP-1 cl avage of M4. R printed with permission from [50].
The relevance of the availability of GASGER, a relatively low affinity integrin binding
site [27] is unclear. It would seem that platelets could bind GPVI and GASGER cooper-
atively based on their proximity [21]. Since the fibril surface within each D-period has
an irregular topology with ridges and valleys akin to that of concrete rebar, we mapped
the position of the mos exposed functional sequences of collagen on the fibril surface;
this revealed that the C-terminal portion of collagen is located at the apex of the fibril’s
ridges, making it the exposed part of collagen, and thus freely accessible to cells and
macromolecules [50]. Notably, the collagen sequences comprising the recessed portions or
valleys of the fibril surface carry out structural duties, including sites for the binding of the
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decorin core protein [60], and in providing possible sites to nucleate and/or accommodate
hydroxyapatite mineral growth in skeletal tissues. Thus, the exterior of the native colla-
gen fibril projects a robust, structural face to the environment, yet is poised to promote
hemostasis in response to tissue injury.
Conditional Cell and Matrix Interaction Domains of the Type I Collagen Fibril
That these findings support a relatively stable, structural role for the collagen fibril
is not surprising, but how can that view be reconciled with the abundant data in the
literature showing collagen to be a dynamic substrate for cell-matrix adhesion, activation,
and differentiation? The answer may come from collaborative studies by several of our
labs, that analyzed the mechanism of collagen remodeling by MMP-1 [21,50,61,62] and
determined that for collagen remodeling to occur, the fibril must be essentially “opened up”
to render the MMP-1 cleavage site available for scission by the enzyme. For this to happen,
the C-terminal telopeptide must first either be proteolytically removed by MMP-1 or
another enzyme (e.g., telopeptidase), and/or pushed aside to expose the MMP-1 cleavage
site on monomer 4 by either local mechanical action at the site on one or more molecules or
via a larger tonal scale strain on the fibril/tissue [47]. Once monomer 4 is cleaved by MMP-1,
other monomers with their host of binding sites, such as monomer 3 containing GFOGER,
monomer 2 containing the Von Willebrand’s Factor (vWF), SPARC, and DDR2 binding
sites become available to cells and bioactive factors. The domain model of the collagen
fibril, when viewed through this lens, suggests that the cell and matrix interaction domains
may be conditionally and mutually exclusively available according to the physiological
state of the tissue in which the fibril resides, in a cyclic process (Figure 5). Thus, in a stable
tissue, the static fibril will be dominated by structural functions of the matrix interaction
domain. Tissue injury causes bleeding into the collagenous stroma, triggering the onset
of the dynamic fibril where the functions of the cell interaction domain take over. Platelet
adhesion to collagen via GPVI-(GPO)5 and possibly integrin receptor-GASGER ligations
occur, leading to platelet aggregation, activation, and hemostasis. Release of MMP-1 from
activated platelets and/or inflammatory cells causes telopeptide removal (or relocation)
to expose sites for MMP-1 cleavage of collagen, and bioactive sites of the collagen fibril
which are functionally crucial in the subsequent events. Moreover, as the fibril is further
denatured and degraded, cryptic epitopes such as the pro-angiogenic sequence RGDKGE
may be exposed [63], and bioactive collagen peptides [64,65] may be released into the
tissue milieux which also promote the tissue regeneration cascade. Inflammatory cells
are activated, enter the tissue, and migrate on the collagenous stroma in response to
chemotactic factors and cytokines released by the activated platelets. The damaged tissue
is removed by inflammatory cells, and tissue cells migrate and proliferate into the site of
injury, while producing a new collagen-rich ECM which in turn promotes terminal tissue
differentiation [14]. Integration and crosslinking of the newly synthesized collagen into a
mature ECM culminates in re-emergence of the quiescent tissue state and the static fibril.
For circumstances aside from tissue injury, such as bone remodeling or tissue growth,
secretion of MMP-1 by cells such as osteoclasts or fibroblasts is also assumed to trigger
collagen remodeling and initiation of the subsequent static to dynamic fibril cycle. Other
possible mechanisms may also trigger the cycle such as cell-assisted mechanical relocation
of the C-terminal telopeptide.
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5. Type III Collagen Interactome
Like type I collagen, type III collagen also aggregates into a fibril. This collagen type
plays crucial roles in embryogenesis [66], hemostasis [67], and wound healing [68,69].
Moreover, it is a vital element of blood vessels and other distensible organs. Collagen
fibrils comprised solely of type III collagen are often found in tissues like the vasculature,
but type III collagen also copolymerizes with type I and V collagens to form heterotypic
fibrils in many tissues, including tendon, skin, and bone [70]. Mutations in the type III
collagen human gene, COL3A1, may result in the vascular type of Ehlers-Danlos syndrome
type IV characterized by wi espread bruising due to rupture of blood vessels; this is
the most serious type of EDS, since pati nts often die suddenly du to ruptu e of large
art ries [71]. Rese rchers also showed that alte ations of the type III: type I collagen ratio
may be responsible for changes in the morphology of collagen fibrils seen, for example, in
Achilles tendinopathies and in the fibrotic skin of lipodermatosclerosis [72,73].
To learn more about the structure-function relationship for type III collagen and to
relate this information to what we have gleaned for type I collagen, we constructed and
analyzed an interactome of human-derived α1(III) homotrimer (not shown) [74]. Several
main observations enabled us to validate our models for both type I and type III collagens.
First, type III collagen has several of the same functional sequences and ligand binding
hot spots as ype I collagen, which occupy similar positi ns in the molecules; this can
be seen by comparing the interactome of type I collagen (Figure 2) with that of type III
collagen previously published (Figure 4) [74]. Thus, the domain model we proposed for
type I collagen also holds for type III. However, as one would expect, type III collagen
has more sites associated with hemostasis. Second, the nearly identical distribution of
charged residues on type III and type I collagens suggests they polymerize in parallel to
form heterotypic fibrils, resulting in the alignment of sites for cell adhesion, intermolecular
crosslinking, and other functions in the composite molecule. Third, we discovered a
possible explanation for why type III collagen has higher Gly, and lower Pro contents
and about twice the number of “atypical amino acid triplets” (e.g., Gly-A a-Ala or Gly-
Gly-Y) compared with the other fibrillar collagens [3]. Since Gly-Pro-Pro triplets are
the predominant contributors to triple-helix stability in fibrillar collagens, and atypical
triplets are destabilizing [75,76], we used the collagen stability calculator [77] to plot the
stability of the type III collagen molecule along its length according to its amino acid triple
composition. We observed that in three locations on the type III collagen fibril, atypical
amino acid triplets co-localized, predicting three major regions of decreased stability. We
thus proposed a “flexi-rod” model for type III collagen in which confluences of atypical
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triplets create flexible domains, allowing focal expansion or deformation of several discrete
fibril regions (Figure 6) [74]. The intervening rod-like regions adopt the rigid triple helical
conformation and assume crucial functions like cell/ligand binding and proteolysis. Our
model may explain how type III collagen’s unique complement of atypical amino acid
triplets confers the molecular flexibility or pliability, a hallmark of the tissues in which
this molecule predominates—such as embryonic or newborn skin, and distensible organs
including blood vessels and the uterus.
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6. Collagen Structure-Function Studies Inform Bioengineering Applications
6.1. Anti-Collagen Antibodies
In the context of fibril-ligand interactions, the C-terminal telopeptide region contains
some of the most significant interaction sites [22,61,62]. As stated above, this is partly due
to its occupying the “up” ridge of the pleated gap-overlap D-periodic structure, with the
C-terminal telopeptide jutting out into the milieu (Figures 1 and 4). It is also because the
radial organization of the microfibril leaves the C-terminal telopeptides on the outside of
the fibril [62]. Thus, this region appears available to interact with immunoglobulins and
immunoglobulin-like receptors which may play prominent roles in matrix remodeling and
antigen recognition [54,59]. The presence of these interaction sites “makes the C-terminal
area of the mature collagen fibril an important region for receptor-mediated activation of
cells, inflammation, cellular recruitment, and prevention of apoptosis” [59].
Recent studies raised antibodies against human collagen [78], that were later shown
to bind the (GPO)5 sequence located at the junction of the triple helix and C-terminus,
revealing novel immunologically relevant properties at the gap-overlap interface [59]. The
binding brought the antibody into the range of the tyrosine residues found exclusively
within the telopeptides. This is significant due to the importance of tyrosine to the function
of OSCAR, an immunoglobulin-like activating receptor of the leukocyte complex [54,79].
This receptor is expressed at high levels in osteoclasts. When bound to collagen, OSCAR
triggers several signaling pathways involved in the modulation of matrix remodeling and
immune cell behaviors. Similar to the anti-(GPO)5 antibody, odeling of OSCAR binding
to collagen de onstrated preference for the same binding site.
6.2. Collagen Fibrillogenesis as a Potential Anti-Fibrotic Target
Knowing specific roles of collagen molecules and fibrils allows their targeting to
achieve therapeutic effects. For example, one of our research groups targeted collagen
fibrillogenesis to block the growth of fibril-rich scars formed in response to injury [80,81].
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While fibrillogenesis is a crucial element of the mechanism that maintains physiological
homeostasis of connective tissues, excessive collagen biosynthesis, and accelerated fibril
formation define fibrotic diseases. Regardless of the etiology and tissue-specific pathways
of these diseases, it is collagen-rich fibrillar deposits that disrupt vital functions of fibrotic
tissues and organs. For instance, in pulmonary fibrosis, dense collagen-rich tissue obstructs
the exchange of gases, thereby limiting blood oxygenation [82]. Moreover, excessive
formation of collagen-rich scars in the skin, peripheral nerves, vocal cords, cornea, and
other tissues severely limits their vital functions [83–86].
Currently, there are no therapeutics available that reduce fibrosis effectively and
safely. The main targets that may limit the fibrotic response to tissue injury include pro-
fibrotic inflammation and activation of pro-fibrotic cells. These targets are nonspecific
intracellular processes that control not only the accelerated production of elements of the
scar tissue, most notably collagen, but also other processes not associated with fibrosis. In
an attempt to target fibrosis specifically and safely, one of our research groups identified
collagen fibrillogenesis as an attractive anti-fibrotic target [80]. The rationale for selecting
fibrillogenesis was that, regardless of the type of injury or its anatomical location, collagen
fibrils are the main element of the fibrotic tissue formed due to excessive scarring. This
notion is illustrated by the fact that collagenous fibrils comprise over ninety-five percent
of the dry mass of pulmonary scars [87]. To attack fibrillogenesis therapeutically, our
group selected collagen telopeptides as the ultimate target. As demonstrated by various
studies, telopeptides drive the collagen-collagen binding interaction that plays a crucial
role in the nucleation and growth of the fibril [56,88]. Thus, blocking telopeptide-mediated
interactions inhibits collagen fibril formation in a concentration-dependent manner [80,89].
Subsequently, utilizing a de novo fibril formation experimental system, we showed that
a monoclonal antibody targeting an epitope within the C-terminal telopeptide of the
α2(I) chain—its C-terminal telopeptide (α2Ct)—inhibits fibril formation in vitro and in
an organotypic model of skin fibrosis [80,89]. These observations strongly suggested
that blocking type I collagen fibrillogenesis may reduce the formation of fibrotic tissues
in vivo. More recently, we confirmed the anti-fibrotic effects of the anti-α2Ct monoclonal
antibody in vivo [80,81]. Moreover, we demonstrated that the anti-α2Ct antibody binds
both free, intact type I procollagen and type I collagen molecules [80]. Consequently,
this antibody inhibits the nucleation step in fibril formation by blocking the assembly
of collagen monomers. Its interaction with mature fibrils, however, is less understood.
One study that utilized type I collagen fibrils formed de novo demonstrated, however,
that the antibody interacted with the gap region of the type I collagen fibril [89]. Since
these fibrils were formed in vitro and contained type I collagen only, there were no other
macromolecules present that could block the access to the gap region in the fibrils, making
the in vivo relevance of these data unclear.
In the context of its anti-fibrotic application, determining potential mechanisms of
the anti-α2Ct antibody’s binding interactions with the collagen fibrils is crucial because:
(i) binding of the antibody to growing, immature fibrils would inhibit their further growth,
and (ii) binding of the antibody to the mature fibrils could reduce its bioavailability. Thus,
we carried out molecular binding simulations between the α2Ct antibody and C-terminus
of type I collagen as detailed below.
6.3. Modeling of Anti-α2Ct Antibody-Collagen Fibril Interactions
6.3.1. Collagen C-Terminus
To illustrate the possible interaction between the anti-α2Ct antibody and the
C-terminus of human type I collagen, we employed the rat tendon X-ray diffraction model
of the type I collagen fibril published by one of our groups [18]; however the predicted
epitope, or sequence for the binding of the antibody to the α2Ct of the rat protein is not
a perfect match with that of the human protein against which the antibody was raised
(Table 1). The sequences are reasonably homologous between rat, human, and other ver-
tebrates commonly used in research (Table 1); however, the α2Ct epitope of the human
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protein GGGYDFGYDGDFYRA, appears to be truncated in the X-ray diffraction model
of the rat protein to: xGGYDF (where x is either G or S). The epitope is however clearly
located at the exterior of the collagen fibril in the highly exposed C-terminus as expected.
Although the molecular sequence database indicates that the α2 rat sequence is longer
than that seen in the molecular model of the rat collagen microfibril, the electron density
near the C-terminus is only well-defined around the α1 chains (Figure 7). This indicates
that the α2 chain in the rat is not as long as the sequence data suggests, or that its full
sequence is present in the fibril but that its C-terminus is significantly disordered and not
discernible by X-ray diffraction. Thus, for the purposes of this review we compensated
for these discrepancies by extending the rat α2 chain by nine amino acids GFEGGFYRA
from the rat sequence (Table 1) in our modeling simulations. Even in an extended and
unfolded confirmation, we observed that the α2Ct epitope is the most exposed of all of
the α chains (Figure 7), while still in position to precisely define the interface between
the gap and overlap zones of the fibril [18]. Therefore, on balance of these considerations,
the α2Ct epitope appears to be fully available on the collagen fibril for interactions with
macromolecules such as a single chain variable fragment (scFv) variant of the anti-α2Ct
antibody. Even if in reality there is some variation, disorder, or if “tucked” alongside one
of the α1 peptides, the telopeptide site on the outside of the fibril is relativity uncluttered
and should still present a highly viable target for the antibody.
Table 1. Ct domain from six vertebrates.
Homo sapiens * GGGYDFGYDGDFYRA
Oryctolagus cuniculus * GGGYDFGYDGDFYRA




* Putative binding epitopes for the anti-α2Ct antibody, underlined. Sequences are from the National Center for
Biotechnology Information (USA).
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Figure 7. X-ray diffraction model of the C-terminal telopeptide region of the rat type I collagen 
microfibril. The truncated α2(I) chain is shown in cyan (see text). The electron density defining the 
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dark blue, fold back on themselves. The anti-fibrotic antibody binding sequence on human colla-
gen—the α2Ct epitope—can be accommodated within the limits of the C-terminus of the rat pro-
Figure 7. X-ray diffraction model of the C-terminal telopeptide region of the rat type I collagen microfibril. The truncated
α2(I) chain is shown in cyan (see text). The electron density defining the C-terminal region is seen to terminate at the ends
of the C-telopeptides, where the α1(I) chains, in dark blue, fold back on themselves. The anti-fibrotic antibody binding
sequence on human collagen—the α2Ct epitope—can be accommodated within the limits of the C-terminus of the rat
protein, however the homologous sequence on the rat α2(I) chain is not found in the structural electron density model (gray
wireframe, C-terminal electron density indicated; red arrow). To enable molecular modeling of scFv antibody-collagen
interactions with rat collagen, the α2(I) chain of the rat protein was extended C-terminally to include the α2Ct epitope of
the rat/human sequence in the molecular model shown in Figure 8 (see text and Table 1).
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bases for such a binding interaction, and, if such exists, to confirm the model experimen-
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pede collagen deposition in fibrotic scars in vivo, by blocking the attachment of additional 
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dark cyan. Upper figure: scFv antibody with highly water accessible “exposed” regions (mesh surface) color-scaled
towards the red end of the spectrum; green is intermediate and blue is not exposed. Antibody subunits show potentially
complementary binding interactions at α2Ct epitope (see text).
6.3.2. Antibody Variant Used for Modeling
Since the crystal structure of the anti-α2Ct antibody is unavailable, modeling its
binding interaction depends on homol gy-based structural s. Here, we applied a
molecular model of a mini-version of the anti-α2Ct antibody, the scFv. A link r connects
its fragments, corresponding to the original complementary deter-mining regions [89].
Thus, the scFv includes the same domains for epitope binding as the native antibody, as
well as exhibiting comparably selective, high affinity binding to the α2Ct of collagen [89].
Consequently, the scFv offers an excellent model to represent the anti-α2Ct antibody-α2Ct
binding interaction in the context of the collagen fibril. The scFv SwissProt-generated
homology model was obtained without modification. The highly water-accessible “surface
exposed” residues within the variable loops of the antibody were bought into contact with
the molecular dyna ics-generated α2Ct epitope of he collagen C-telopeptid (Figure 8).
There appears to be ample potential for complementary surface interactions between the
molecules, suggesting the α2Ct epitope may serve as a candidate binding site for the scFv
antibody. Further computational studies are required to establish the potential molecular
bases for such a binding interaction, and, if such exists, to confirm the model experimentally.
Based on these preliminary data, we speculate on how the scFv antibody could impede
collagen deposition in fibrotic scars in vivo, by blocking the attachment of additional
collagen molecules to the surfaces of growing fibrils, e.g., via disruption of the function
of the fibrillogenesis control sequences [56] (Figures 2 and 4). In addition to impeding the
gr w h of the fibrils, the antibody-telopeptide interaction may also preven the formation
of new fibrils by blocking telopeptide mediated collagen-c llagen aggregati during the
nucleation phase of fibrillogenesis [56]. Considering that the full-length antibody is about
150 Å in diameter and much greater in size than the scFv, its interaction with the α2Ct may
render neighboring binding sites on the fibril inaccessible; i.e., it may inhibit other collagen
functions aside from fibrillogenesis. Consequently, binding of the anti-α2Ct antibody may
not only exert its anti-fibrotic effect via direct blocking of collagen fibrillogenesis but also
by disrupting other mechanisms underlying complex scar formation.
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6.4. A Broad View on Blocking Matrix Assembly as an Anti-Fibrotic Therapy
The model we propose for the anti-α2Ct antibody-collagen fibril interaction would
provide a blue print for other interactions with anti-fibrotic potential. We realize that
although type I collagen is the main component of fibrotic deposits, other collagenous and
non-collagenous macromolecules also contribute to the fibrotic mass. For instance, the
production of fibronectin is also upregulated in fibrotic processes, and its assembly may
precede that of collagen fibrils. Consequently, a peptide inhibitor of fibronectin fibrillogen-
esis has been shown to exhibit anti-fibrotic properties [90]. Other compounds were also
suggested as inhibitors of collagen fibrillogenesis, and potentially, anti-fibrotic therapeutics.
In one example, researchers employed α-lipoic acid to block a site-specific interaction that
drives collagen fibril assembly [91]. In similar experiments, trigonelline hydrochloride
was shown to be an effective inhibitor of collagen fibrillogenesis [92]. Recently, two small
molecules, nintedanib, and pirfenidone, were approved for the treatment of idiopathic
pulmonary fibrosis (IPF). Although their mechanism of action is not clearly established,
nintedanib is a receptor kinase inhibitor of platelet-derived growth factor receptor and
vascular endothelial growth factor receptor, all of which play roles in the pathology of
IPF. Pirfenidone is an anti-fibrotic, anti-inflammatory, and antioxidant compound with
beneficial effects in organ fibrosis, but its direct targets are not known. In addition to the
cellular effect of these compounds, however, it was demonstrated that they directly block
collagen fibril formation [93]. Furthermore, since type I collagen molecules copolymerize
with type III and type V collagens to form heterotypic fibrils in vivo, we cannot exclude the
possibility that the anti-αCt antibody disrupts the co-assembly process [94,95]. These exam-
ples further justify targeting the assembly of collagen-rich matrices as potential anti-fibrotic
therapies.
7. Collagen-Induced Angiogenesis
In adult mammals, angiogenesis—or new capillary growth from an existing
vasculature—is the single mechanism by which new blood vessels develop [96]. An-
giogenesis is involved in homeostasis and diseases, including for example, solid tumor
growth and metastasis, rheumatoid arthritis, hemangioma formation, and diabetic retinopa-
thy [96]. It is a complex process by which endothelial cells degrade the surrounding ECM,
migrate, proliferate, and differentiate to form new vessels [97]. Angiogenesis depends
upon the interaction of endothelial cells with the ECM via cell surface adhesion molecules
including the integrins, and the activities of growth factors and cytokines [98]. Because
type I collagen is a ubiquitous component of many tissues that undergo angiogenesis
during embryogenesis, it may play a role in promoting normal as well as pathological
angiogenesis. For example, in vivo, angiogenesis is disrupted in the chick embryo by in-
hibiting collagen triple helix formation or fibrillogenesis, using several chemical inhibitors
of those processes. In fact, type I collagen has also been demonstrated to be among the few
optimal scaffolds for the induction of angiogenesis in vitro. Thus, type I collagen synthesis
by endothelial cells [99,100] precedes angiogenesis, and is limited to the vicinity of capillary
tube formation in cultures [101,102]. Furthermore, endothelial cells grown between or
within collagen gels rapidly form capillary tube networks [103,104].
Integrin Receptor Ligation and Clustering in Collagen-Induced Angiogenesis
Our research showed that in vitro, apical type I collagen gels rapidly induce angiogen-
esis in human endothelial cell monolayers (Figure 9) [105]. Further, angiogenesis required
the engagement between the α2β1 integrins of the endothelial cells and the central integrin
binding site, GFOGER, on the collagen molecule [105]. Further studies demonstrated that
in quiescent endothelial cell confluent monolayers, in the absence of exogenous collagen,
the α2β1 integrins concentrated along cell-cell borders. After adding apical collagen gels to
the cultures, the integrins redistributed to apical cell surfaces, aligning with collagen fibers,
which also relocated during angiogenesis [106]. Based on these observations, as well as
on the distribution of integrin binding sites in the type I collagen fibril, we proposed that
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the fibril may function as an ideal substrate for integrin receptor clustering and activation
necessary for angiogenesis [7,107]. Therefore, we next tested whether the polyvalency
of collagen fibrils could be mimicked using antibody-coated polystyrene beads to clus-
ter endothelial cell surface integrins, and thereby induce angiogenesis in the absence of
collagen. It was discovered that clustering of α2β1 integrins, as well as αvβ3 integrins
and PECAM-1, but not of α1 integrins, induced rapid angiogenesis even in the absence
of collagen, whereas those same antibodies, when added alone to cultures, had no effect
(Figure 10) [106]. Thus, the angiogenic property of type I collagen may reside in its ability
to bind and cluster cell surface α2β1 integrins as well as select other endothelial cell surface
receptors.
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8. Bioengineering Applications: Angiogenic Polymers
We previously reviewed strategies to produce angiogenic polymers based on our
understanding at that time of the collagen structure-function relationship and mechanisms
of angiogenesis [7]. Here we will update and expand upon some of those strategies account-
ing for the newer information on these topics. As pointed out previously, type I collagen
from animal sources is an effective angiogenic polymer. Moreover, collagen is easy to
isolate in the lab but is also commercially available at reasonable cost. The collagen prepa-
rations we used to promote angiogenesis consisted of acid soluble, non-pepsinized, type I
collagen from rat tail tendon that were applied to endothelial cells as gels. The angiogenic
properties of collagen required its native, triple helical, and fibrillar conformations [105].
According to the domain model of collagen fibril function, for a collagen fibril to support
angiogenesis, it must have an accessible MMP-1 cleavage site, which must be cleaved by
MMP-1 released by endothelial cells to expose the underlying central integrin binding
site, GFOGER. Indeed it has been reported that growth factor-dependent angiogenesis
in vivo requires MMP-1-mediated cleavage of collagen [107]. Collagen preparations of the
type we used are expected to have most of their telopeptides, with a relatively low density
of intermolecular crosslinking at those regions which should facilitate their removal by
MMP-1. Such non-pepsinized, telopeptide-containing collagen is preferred as an angio-
genic polymer since the presence of telopeptides allows for rapid fibrillogenesis and robust
gel formation in comparison with atelopeptidic collagen produced through pepsinization,
because the latter may not undergo fibrillogenesis or gelation adequately [3].
8.1. Recombinant Super-Angiogenic Collagens
To engineer a super-angiogenic polymer, one may consider creating recombinant
collagens with an enhanced capacity to ligate and cluster endothelial cell integrin receptors.
The most obvious way to do so would be to add integrin binding sequences to surface-
exposed regions of the fibril; based on our structural mapping, those could be placed within
monomer 5 and the gap zone portion of monomer 4. Given the diameter of the integrin
heterodimer of about 10–20 nm, only two or three such receptors could simultaneously
ligate the fibril and be accommodated within the 67 nm D-period. Since there is only one
low affinity integrin binding site on the fibril surface—GASGER, that sequence should be
replaced by the high affinity integrin binding sequence GFOGER. Possibly, up to two other
GFOGER sequences might be inserted elsewhere in the exposed fibril regions, taking care
not to disrupt other functional sites or residues crucial for fibril assembly and integrity
(see Figures 2 and 4). Other type I collagen sequences that should not be removed or
altered in the recombinant protein include those proposed necessary for the angiogenic
properties of collagen: the MMP-1 interaction domain; the MMP-1 cleavage sequence; the
central integrin binding site GFOGER; and the N- and C-terminal heparin binding sites.
Functional sites that may be removed or modified to render them inactive include those
for the binding of SPARC, PEDF, and decorin, all of which may exhibit anti-angiogenic
activities [108–111]. Including C- and N-telopeptides in the polymer would be advanta-
geous for rapid fibrillogenesis and robust gel formation properties of the material, but
removing the capacity for intermolecular crosslinking within the C-terminal telopeptide is
suggested, to render the polymer more easily proteolyzed by MMP-1, a proposed step in
angiogenesis induction by collagen.
8.2. Collagen Mimetics as Angiogenesis Substrates
The discovery and application of collagen mimetics is an emerging field in biotech-
nology, and is reviewed extensively by Xu and Kirchner in this issue. The “bare bones”
of the collagen fibril vis-a-vis its angiogenesis promoting activity appears to be its ability
to ligate, and by virtue of its multivalency, cluster α2β1 integrin receptors. Theoretically,
several classes of novel materials may mimic that activity and substitute for collagen. One
class comprises two versions of synthetic “sticky-ended” collagen-like peptides that self-
assemble into triple helices and higher ordered structures resembling collagen fibrils, and
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in one case also forms stable hydrogels [112,113]. The peptides can carry the high affinity
integrin binding site GFOGER crucial for angiogenesis promotion, as well as the sequence
of type I collagen rendering the polymers sensitive to MMP-1 degradation; the latter would
ensure its shorter in vivo half-life if desired. Such peptides could also be modified to
promote hemostasis instead, by carrying GPO5, and in some cases, also GFOGER if both
hemostatic and pro-angiogenic activities are desired. A second class of collagen mimics is
suggested by our in vitro angiogenesis studies [106]. Thus, biodegradable beads (e.g., albu-
min, polycaprolactone, or poly(D,L-lactide-coglycolide) among others) of about 1–5 µm
diameters and onto which anti-α2β1 integrin antibodies are adsorbed or covalently linked
may also mimic the angiogenic activities of collagen. Instead, it may be of interest to affix
anti-α2β1 integrin antibodies at high densities on biodegradable fibrous polymer filaments
to achieve a more collagen-like substrate for angiogenesis. The angiogenic collagen mimics
described here may in several respects be preferable to using native or recombinant colla-
gen as angiogenic substrates to avoid the drawbacks of using large, complex proteins from
natural sources, including the presence of undesirable binding activities, batch-to-batch
variations, and potential immunogenicity, among other considerations.
9. Summary
Here we attempted to reconcile the biology of the type I collagen fibril with its
complex three-dimensional structure. Data suggest that in quiescent tissues, the fibril
assumes structural duties, but tissue trauma may lead to collagen proteolysis, exposing a
host of cell- and ligand-binding sites crucial for tissue regeneration. Moreover, our research
helped identify a possible mechanism of action of an anti-fibrotic collagen-binding antibody,
and develop non-collagenous agents that mimic collagen’s ability to cluster endothelial
integrins and promote angiogenesis. Further structure-function analysis of collagen fibrils
in various physiologic contexts will help elucidate poorly-understood aspects of collagen
biology like fibril assembly and biomineralization, and facilitate the discovery of novel
therapies to combat human pathologies where collagen plays prominent roles.
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